The right pick, Capricor Therapeutics and Apnimed Inc. stock surges on analyst upgrades

Capricor Therapeutics Inc (NASDAQ:CAPR) shares rose 15.7% Tuesday following an upgrade from Oppenheimer analyst Leland Gershall, who raised the stock from Perform to Outperform with a price target of $54.

Apnimed Inc. (NASDAQ:APMD) shares rose 10.3% on Tuesday following multiple analyst initiations with positive ratings on the sleep apnea treatment developer.

Cantor Fitzgerald analyst Josh Schimmer initiated coverage with an Overweight rating and a $60 price target, representing approximately 2x upside from the current share price of around $32. BofA Securities analyst Jason Gerberry began coverage with a Buy rating and a $41 price target, while Evercore ISI analyst Umer Raffat and LifeSci Capital both initiated coverage with Outperform ratings. LifeSci Capital set a $50 price target.